Dayton Misfeldt has a twenty-year history with Bay City Capital primarily investing in biopharmaceutical companies. He brings significant experience spanning multiple market cycles working with management teams with an eye toward strategic decision making, business development, and positioning for exit opportunities.
Past investments have included Cadence Pharmaceuticals (acquired by Mallinckrodt), Civitas Therapeutics (acquired by Acorda Therapeutics), Dermira Inc (acquired by Lilly), MAP Pharmaceuticals (acquired by Allergan), Nextwave Pharmaceuticals (acquired by Pfizer), Oculex Pharmaceuticals (acquired by Allergan), and Pharmion Corporation (acquired by Celgene), among others.
Prior to Bay City Capital, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. He began his career at LifeScience Economics. Mr. Misfeldt received a BA in Economics from the University of California, San Diego.